Check Your Eligibility
Answer a few questions to see if you may qualify for this trial.
Step 1 of 8
Do you have a diagnosis of relapsed or refractory neuroblastoma, osteosarcoma, uveal melanoma, breast cancer, or another solid tumor that is GD2 positive and has not responded to standard treatment?
This trial is designed for patients whose cancers express a protein called GD2 and have stopped responding to standard treatments. Your cancer must have either come back after initial treatment or never responded to initial treatment.
Show original medical criteria
GD2-positive cancer diagnosis with documented relapsed or refractory disease is the primary inclusion criterion for this CAR-T cell therapy trial
This is informational only — not medical advice. Always discuss eligibility with your oncologist.